CLINICAL TRIALS PROFILE FOR RESLIZUMAB
✉ Email this page to a colleague
All Clinical Trials for reslizumab
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00635089 ↗ | Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis | Completed | Cephalon | Phase 3 | 2008-07-01 | This study is an open-label study where all subjects will receive active drug, reslizumab. Subjects are able to enter this trial only through completion of study Res-05-0002 (NCT00538434). The goal of the study is to show longer term safety and efficacy in pediatric subjects who have eosinophilic esophagitis. |
| NCT00635089 ↗ | Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis | Completed | Ception Therapeutics | Phase 3 | 2008-07-01 | This study is an open-label study where all subjects will receive active drug, reslizumab. Subjects are able to enter this trial only through completion of study Res-05-0002 (NCT00538434). The goal of the study is to show longer term safety and efficacy in pediatric subjects who have eosinophilic esophagitis. |
| NCT01111305 ↗ | Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2010-04-01 | Diethylcarbamazine citrate (DEC) treatment of Loa loa infection is complicated by the development of severe adverse reactions that are correlated with the number of circulating microfilariae in the blood. The cause of these reactions is unknown, but they are accompanied by a dramatic interleukin-5 (IL-5)-dependent increase in eosinophilia and evidence of eosinophil activation. This randomized, placebo-controlled, double-blind pilot study (conducted at the NIH Clinical Center) will assess whether and to what extent the administration of reslizumab (Cinquil ), a humanized monoclonal antibody directed against IL-5, given 3 to 7 days before administration of the anthelminthic drug DEC (at 3 mg/kg 3 times daily for 21 days), prevents the development of eosinophilia in 10 adult subjects with Loa loa infection and 0-5000 microfilariae/mL. Secondary outcomes will include the severity of post-treatment effects, markers of eosinophil activation, and effects of reslizumab on microfilarial clearance. |
| NCT01270464 ↗ | A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 | 2011-02-01 | The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic asthma as assessed by the overall change from baseline in forced expiratory volume in 1 second (FEV1). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for reslizumab
Condition Name
Clinical Trial Locations for reslizumab
Trials by Country
Clinical Trial Progress for reslizumab
Clinical Trial Phase
Clinical Trial Sponsors for reslizumab
Sponsor Name
